GT Biopharma posts Q3 net loss as R&D expenses rise
GTBP•GT Biopharma reported a Q3 net loss of $3.5 million, compared with net income a year earlier. R&D expenses rose, SG&A expenses declined, and the company ended the quarter with $10 million in cash, which it expects to fund operations into Q3 2027.
1. Quarterly results
GT Biopharma reported a Q3 net loss of $3.5 million, compared with net income in the prior-year quarter. Income from operations was negative $3.5 million.
2. Expenses and cash
R&D expenses rose year over year, primarily due to higher material costs for clinical development of GTB-3650 and GTB-5550. SG&A expenses declined as consulting and marketing costs fell. The company ended Q3 with $10 million in cash and anticipates a cash runway into Q3 2027.
3. Program outlook
GT Biopharma expects to provide updates on both Phase 1 programs in Q4 2026. Initiation of a Phase 1 trial for GTB-5550 in multiple myeloma depends on the timing of grant funding.




